Skip to Content

Moexipril Hydrochloride

Class: Angiotensin-Converting Enzyme Inhibitors
- ACE Inhibitors
VA Class: CV800
Chemical Name: (3S-(2(R*(R*)),3R*))-2-(2-((1 -(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid monohydrochloride
Molecular Formula: C27H34N2O7•ClH
CAS Number: 82586-52-5

Medically reviewed on Mar 19, 2018


  • May cause fetal and neonatal morbidity and mortality if used during pregnancy.1 83 110 111 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

  • If pregnancy is detected, discontinue as soon as possible.1 111


Nonsulfhydryl ACE inhibitor.1

Uses for Moexipril Hydrochloride


Management of hypertension (alone or in combination with other classes of antihypertensive agents).1 2 5 25 83 500

ACE inhibitors are recommended as one of several preferred drugs for the initial management of hypertension; other options include angiotensin II receptor antagonists, calcium-channel blockers, and thiazide diuretics.501 502 503 504 While there may be individual differences with respect to specific outcomes, these antihypertensive drug classes all produce comparable effects on overall mortality and cardiovascular, cerebrovascular, and renal outcomes.500 501 502 504 Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).500 501 502 503 504 515

ACE inhibitors may be preferred in hypertensive patients with heart failure, ischemic heart disease, diabetes mellitus, chronic kidney disease, or cerebrovascular disease or post-MI.500 501 502 504 520 523 524 525 526 527 534 535 536 543

Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to ACE inhibitors.25 83 92 93 108 109 500 501 504 However, diminished response to an ACE inhibitor is largely eliminated when administered concomitantly with a calcium-channel blocker or thiazide diuretic.25 83 500 504

The optimum BP threshold for initiating antihypertensive drug therapy is controversial.501 504 505 506 507 508 515 523 530 Further study needed to determine optimum BP thresholds/goals; individualize treatment decisions.501 503 507 515 526 530

JNC 7 recommends initiation of drug therapy in all patients with uncomplicated hypertension and BP ≥140/90 mm Hg;500 JNC 8 panel recommends SBP threshold of 150 mm Hg for patients ≥60 years of age.501 Although many experts agree that SBP goal of <150 mm Hg may be appropriate for patients ≥80 years of age,502 504 505 530 application of this goal to those ≥60 years of age is controversial, especially for those at higher cardiovascular risk.501 502 505 506 508 511 515

In the past, initial antihypertensive drug therapy was recommended for patients with diabetes mellitus or chronic kidney disease who had BP ≥130/80 mm Hg;500 503 current hypertension management guidelines generally recommend a BP threshold of 140/90 mm Hg for these individuals (same as for the general population of patients without these conditions), although a goal of <130/80 mm Hg may still be considered.501 502 503 504 520 530 535 536 541

Heart Failure

Management of heart failure, usually in conjunction with other agents such as cardiac glycosides, diuretics, and β-adrenergic blocking agents (β-blockers).10 11 12 14 96 524 800

Some evidence indicates that therapy with an ACE inhibitor (enalapril) may be less effective than angiotensin receptor-neprilysin inhibitor (ARNI) therapy (e.g., sacubitril/valsartan) in reducing cardiovascular death and heart failure-related hospitalization.702 800

ACCF, AHA, and the Heart Failure Society of America (HFSA) recommend that patients with chronic symptomatic heart failure and reduced left ventricular ejection fraction (LVEF) (NYHA class II or III) who are able to tolerate an ACE inhibitor or angiotensin II receptor antagonist be switched to therapy containing an ARNI to further reduce morbidity and mortality.800

Diabetic Nephropathy

A recommended agent in the management of patients with diabetes mellitus and persistent albuminuria who have modestly elevated (30–300 mg/24 hours) or higher (>300 mg/24 hours) levels of urinary albumin excretion; slows rate of progression of renal disease in such patients.103 104 105 106 107 520 535 536

Moexipril Hydrochloride Dosage and Administration


BP Monitoring and Treatment Goals

  • Carefully monitor BP during initial titration or subsequent upward adjustment in dosage.500 501

  • When available, use evidence-based dosing information (i.e., dosages shown in randomized controlled trials to reduce complications of hypertension) to determine target dosages; target dosages usually can be achieved within 2–4 weeks but may take up to several months.501

  • If adequate BP response not achieved with a single antihypertensive agent, add a second drug with demonstrated benefit; if goal BP still not achieved with optimal dosages of 2 antihypertensive agents, add a third drug.501 May maximize dosage of the first drug before adding a second drug, or add a second drug before maximizing dosage of the initial drug.501

  • Consider initiating antihypertensive therapy with a combination of drugs if patient's BP exceeds goal BP by >20/10 mm Hg.500 501 503 504

  • Goal is to achieve and maintain optimal control of BP; individualize specific target BP based on consideration of multiple factors, including patient age and comorbidities, and currently available evidence from clinical studies.500 501 (See Hypertension under Uses.)


Oral Administration

Administer orally once or twice daily 1 hour before meals.1 3 83


Available as moexipril hydrochloride; dosage expressed in terms of the salt.1 83


Moexipril Therapy

Initially, 7.5 mg once daily in patients not receiving a diuretic.1 5

In patients currently receiving diuretic therapy, discontinue diuretic, if possible, 2–3 days before initiating moexipril or cautiously increase salt intake.1 8 9 10 11 12 13 14 37 46 May resume diuretic therapy if BP not controlled adequately with moexipril alone.1 28 29 30 39 If diuretic cannot be discontinued, give lower initial moexipril dose (3.75 mg) under close medical supervision until BP has stabilized.8 10 11 12 13 14 83 84

Usual dosage: 7.5–30 mg daily, given in 1 dose or 2 divided doses.1 83 500

If effectiveness diminishes toward end of dosing interval in patients treated once daily, consider increasing dosage or administering drug in 2 divided doses.1

If intolerable adverse effects occur, consider dosage reduction; if adverse effects worsen or fail to resolve, may need to discontinue and switch to another antihypertensive drug class.501

Moexipril/Hydrochlorothiazide Fixed-combination Therapy

Manufacturer states fixed-combination preparation should not be used for initial antihypertensive therapy.83

If BP is not adequately controlled by monotherapy with moexipril, can switch to the fixed-combination preparation containing moexipril hydrochloride 7.5 mg and hydrochlorothiazide 12.5 mg, moexipril hydrochloride 15 mg and hydrochlorothiazide 12.5 mg, or moexipril hydrochloride 15 mg and hydrochlorothiazide 25 mg.83 Adjust dosage of either or both drugs according to patient’s response.83

Prescribing Limits



Usually, maximum 30 mg daily.1 Dosages >60 mg daily have not been extensively evaluated in hypertensive patients.1 5

Special Populations

Renal Impairment


Initially, 3.75 mg once daily in patients with severe renal impairment (Clcr ≤40 mL/minute); titrate until BP is controlled or to maximum of 15 mg daily.1

Moexipril/hydrochlorothiazide fixed combination is not recommended in patients with severe renal impairment.83

Volume- and/or Salt-depleted Patients

Correct volume and/or salt depletion prior to initiation of therapy or initiate therapy under close medical supervision using lower initial dosage.1

Cautions for Moexipril Hydrochloride


  • Known hypersensitivity to moexipril, any ingredient in the formulation, or any other ACE inhibitor.1 83

  • History of angioedema with prior ACE inhibitor treatment.1 83

  • Concomitant therapy with aliskiren in patients with diabetes mellitus.1 83



Fetal/Neonatal Morbidity and Mortality

Possible fetal and neonatal morbidity and mortality when used during pregnancy.1 111 (See Boxed Warning.) Such potential risks occur throughout pregnancy, especially during the second and third trimesters.111

Also may increase the risk of major congenital malformations when administered during the first trimester of pregnancy.110 111

Discontinue ACE inhibitors (e.g., moexipril) as soon as possible when pregnancy is detected, unless continued use is considered lifesaving.1 110 111 Nearly all women can be transferred successfully to alternative therapy for the remainder of their pregnancy.75


Possible symptomatic hypotension, particularly in volume- and/or salt-depleted patients (e.g., those with restricted salt intake, treated with diuretics, undergoing dialysis, with nausea or vomiting).1

Risk of marked hypotension, sometimes associated with oliguria and azotemia, and rarely acute renal failure and death in patients with heart failure with or without associated renal insufficiency.1 Severe hypotension may result in MI or stroke in patients with ischemic heart disease, aortic stenosis, or cerebrovascular disease.1 12 34 35 36

Hypotension may occur in patients undergoing surgery or during anesthesia with agents that produce hypotension; recommended treatment is fluid volume expansion.1

To minimize potential for hypotension, consider recent antihypertensive therapy, extent of BP elevation, sodium intake, fluid status, and other clinical conditions.1 May minimize potential for hypotension by withholding diuretic therapy and/or increasing sodium intake for 2–3 days prior to initiation of moexipril.1

Transient hypotension is not a contraindication to additional doses; may reinstate therapy cautiously after BP is stabilized (e.g., with volume expansion).1

Initiate therapy in patients with heart failure (with or without associated renal insufficiency) under close medical supervision; monitor closely for first 2 weeks following initiation of moexipril or any increase in moexipril or diuretic dosage.1


Neutropenia and agranulocytosis reported with ACE inhibitors.1 83 Risk of neutropenia appears to depend principally on degree of renal impairment and presence of collagen vascular disease (e.g., systemic lupus erythematosus, scleroderma); risk with moexipril is unknown.1 83

Consider monitoring leukocytes in patients with collagen vascular disease, especially if renal impairment exists.1 83

Hepatic Effects

Clinical syndrome that usually is manifested initially by cholestatic jaundice and may progress to fulminant hepatic necrosis (occasionally fatal) reported rarely with ACE inhibitors.1

If jaundice or marked elevation of liver enzymes occurs, discontinue drug and monitor patient.1

Sensitivity Reactions

Anaphylactoid reactions and/or angioedema possible; if associated with laryngeal edema, may be fatal.1 83 Immediate medical intervention (e.g., epinephrine) required for involvement of tongue, glottis, or larynx.1 83 Intestinal angioedema possible; consider in differential diagnosis of patients who develop abdominal pain.1 83

Anaphylactoid reactions reported in patients receiving ACE inhibitors while undergoing LDL apheresis with dextran sulfate absorption1 51 52 83 or following initiation of hemodialysis that utilized high-flux membrane.1 47 48 49 83

Life-threatening anaphylactoid reactions reported in at least 2 patients receiving ACE inhibitors while undergoing desensitization treatment with hymenoptera venom.1 83

Contraindicated in patients with a history of angioedema associated with ACE inhibitors.1 83

General Precautions

Renal Effects

Inhibition of renin-angiotensin-aldosterone (RAA) system may cause renal impairment, and, rarely, acute renal failure and/or death in susceptible patients (e.g., hypertensive patients with severe heart failure).1 83

Deterioration in renal function possible in hypertensive patients with unilateral or bilateral renal artery stenosis; generally reversible following discontinuance of ACE inhibitors and/or diuretic.1 83

Closely monitor renal function for first few weeks following initiation of therapy and periodically thereafter in such patients.1 83 Some patients may require dosage reduction or discontinuance of ACE inhibitor or diuretic.1 83

Effects on Potassium

Possible hyperkalemia, especially in patients with renal impairment or diabetes mellitus and those receiving drugs that can increase serum potassium concentration (e.g., potassium-sparing diuretics, potassium supplements, potassium-containing salt substitutes).1 (See Specific Drugs under Interactions.)

Monitor serum potassium concentration carefully in these patients.1


Persistent and nonproductive cough; resolves after drug discontinuance.1


Hypotension may occur during surgery or anesthesia with agents that produce hypotension; moexipril may block the effects on compensatory renin release in such patients.1 83 May correct such hypotension by volume expansion.1 83

Use of Fixed Combinations

When moexipril is used in fixed combination with hydrochlorothiazide, consider the cautions, precautions, and contraindications associated with hydrochlorothiazide.83

Specific Populations


Category D.1 83

Can cause fetal and neonatal morbidity and mortality when administered to a pregnant woman.1 83 (See Fetal/Neonatal Morbidity and Mortality under Cautions and see Boxed Warning.)


Not known whether moexipril is distributed into milk.1 Caution advised if used in nursing women.1

Pediatric Use

If oliguria or hypotension occurs in neonates with a history of in utero exposure to moexipril, support BP and renal function; exchange transfusions or dialysis may be required.1 83 (See Fetal/Neonatal Morbidity and Mortality under Cautions.)

Safety and efficacy not established.1

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.1 Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and potential for concomitant disease and drug therapy.1

Renal Impairment

Systemic exposure to moexipril and moexiprilat may be increased.1 Initial dosage adjustment recommended in patients with severe renal impairment.1 (See Renal Impairment under Dosage and Administration.)

Moexipril/hydrochlorothiazide fixed combination is not recommended in patients with severe renal impairment.83

Black Patients

BP reduction may be smaller in black patients compared with patients of other races.25 83 92 93 108 109 (See Hypertension under Uses.)

Higher incidence of angioedema reported with ACE inhibitors in black patients compared with other races.1 500

Common Adverse Effects

Cough, dizziness, diarrhea, flu syndrome, fatigue, pharyngitis, flushing, rash, myalgia.1

Interactions for Moexipril Hydrochloride

Specific Drugs




ACE inhibitors

Increased risk of renal impairment, hyperkalemia, and hypotension1 83

Generally, avoid concomitant use; monitor BP, renal function, and electrolytes if used concomitantly1 83


Increased risk of renal impairment, hyperkalemia, and hypotension1 83

Generally, avoid concomitant use; monitor BP, renal function, and electrolytes if used concomitantly1 83

Angiotensin II receptor antagonists

Increased risk of renal impairment, hyperkalemia, and hypotension1 83

Generally, avoid concomitant use; monitor BP, renal function, and electrolytes if used concomitantly1 83

Anticoagulants, oral

Clinically important interaction not observed1


Clinically important interaction not observed1


Clinically important interaction not observed1


Increased hypotensive effect1

If possible, discontinue diuretic before initiating moexipril1 (see Dosage under Dosage and Administration)

Diuretic, potassium-sparing (amiloride, spironolactone, triamterene)

Enhanced hyperkalemic effect1

Use with caution; monitor serum potassium concentrations frequently1


Nitroid reactions reported rarely in patients receiving concomitant therapy with sodium aurothiomalate and an ACE inhibitor1 83


Increased serum lithium concentrations; possible toxicity1

Use with caution; monitor serum lithium concentration frequently1

NSAIAs (including COX-2 inhibitors)

May result in deterioration of renal function, including possible renal failure, in geriatric patients, volume-depleted patients, or patients with compromised renal function;1 83 effects usually reversible1 83

Monitor renal function periodically 1 83

Potassium supplements or potassium-containing salt substitutes.

Enhanced hyperkalemic effect1

Use with caution; monitor serum potassium concentrations frequently1

Moexipril Hydrochloride Pharmacokinetics



About 13% of oral dose is absorbed.1 Peak plasma concentration of moexiprilat is achieved within about 1.5 hours.1


Following a single oral dose, antihypertensive effects are observed within about 1 hour with peak BP reduction at 3–6 hours.1

During chronic therapy, maximum antihypertensive effect with any dose is achieved after 4 weeks.1


Antihypertensive effect of a single dose persists for about 24 hours.1


Food reduces peak plasma concentration of moexipril; administer 1 hour before meals.1

Special Populations

In patients with cirrhosis, peak plasma concentration and AUC of moexipril following a single oral dose were increased, while peak plasma concentration of moexiprilat was decreased and AUC of moexiprilat was increased.1

In patients with renal impairment, increased moexipril and moexiprilat concentrations.1



Not known whether distributed into milk.1

Plasma Protein Binding

Moexiprilat: 50%.1



Metabolized in the liver, principally to an active metabolite, moexiprilat.1

Elimination Route

Following oral administration, eliminated in feces (53%), principally as moexiprilat, and to a lesser extent in urine (13%).1

Following IV administration, eliminated principally in urine, as moexiprilat (40%) and moexipril (26%), and to lesser extent in feces (about 20%, mainly as moexiprilat).1


Moexiprilat: 12 hours.1

Special Populations

In patients with renal impairment (Clcr 10–40 mL/minute), threefold to fourfold increase in moexiprilat half-life.1





Tight containers at 15–30°C.1


  • Prodrug; not pharmacologically active until hydrolyzed in the liver to moexiprilat.1

  • Suppresses the renin-angiotensin-aldosterone system.1

Advice to Patients

  • Risk of angioedema, anaphylactoid reactions, or other sensitivity reactions.1 Importance of reporting sensitivity reactions (e.g., edema of face, eyes, lips, tongue, or extremities; hoarseness; swallowing or breathing with difficulty) immediately to clinician and of discontinuing the drug.1

  • Risk of hypotension.1 Importance of informing clinicians promptly if lightheadedness or fainting occurs.1 Importance of adequate fluid intake; risk of volume depletion with excessive perspiration, dehydration, vomiting, or diarrhea.1

  • Importance of reporting signs of infection (e.g., sore throat, fever).1

  • Risk of hyperkalemia.1 83 Importance of avoiding use of potassium supplements or salt substitutes containing potassium without consulting a clinician.1 83

  • Importance of taking moexipril 1 hour before meals.1

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.1

  • Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.1 Risks of use during pregnancy; importance of discussing other options for hypertension treatment if pregnancy occurs.1 110 111

  • Importance of advising patients of other important precautionary information.1 (See Cautions.)


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Moexipril Hydrochloride


Dosage Forms


Brand Names



Tablets, film-coated

7.5 mg*

Moexipril Hydrochloride Tablets

15 mg*

Moexipril Hydrochloride Tablets

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Moexipril Hydrochloride Combinations


Dosage Forms


Brand Names



Tablets, film-coated

7.5 mg with Hydrochlorothiazide 12.5 mg*

Moexipril Hydrochloride and Hydrochlorothiazide Tablets

15 mg with Hydrochlorothiazide 12.5 mg*

Moexipril Hydrochloride and Hydrochlorothiazide Tablets

15 mg with Hydrochlorothiazide 25 mg*

Moexipril Hydrochloride and Hydrochlorothiazide Tablets

AHFS DI Essentials. © Copyright 2019, Selected Revisions March 19, 2018. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.


1. Apotex. Moexipril hydrochloride tablets prescribing information. Milwaukee, WI; 2012 Dec.

2. Dickstein K, Aarsland T, Ferrari P et al. Comparison of the efficacy of three dose levels of moexipril versus placebo as add-on therapy to hydrochlorothiazide in patients with moderate hypertension. J Cardiovasc Pharmacol. 1994; 24:247-55.

3. Grass GM, Morehead WT. Evidence for site-specific absorption of a novel ACE inhibitor. Pharm Res. 1989; 6:759-65.

4. White WB, Whelton A, Fox AAL et al. Tricenter assessment of the efficacy of the ACE inhibitor, moexipril, by ambulatory blood pressure monitoring. J Clin Pharmacol. 1995; 35:233-8.

5. Chrysant SG, Fox AAL, Stimpel M. Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients. Am J Hyperten. 1995; 8: 418-21.

6. Stimpel M, Loh IK. Moexipril versus captopril in patients with mild to moderate hypertension. Am J Hyperten. 1995; 8:183A.

7. White WB, Fox AAL, Stimpel M. Long-term efficacy and safety of moexipril in the treatment of hypertension. J Hum Hyperten. 1994; 8: 917-21.

8. Bristol-Myers Squibb Co. Capoten tablets (captopril tablets) prescribing information. In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995:710-4.

9. Hoechst-Roussel Pharmaceuticals Inc. Altace (ramipril) prescribing information. In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995:1124-6.

10. Parke Davis. Accupril (quinapril hydrochloride) tablets prescribing information. Morris Plains, NJ; 2001 Mar.

11. Merck. Prinivil (lisinopril) tablets prescribing information. Whitehouse Station, NJ; 2002 Jan.

12. Merck & Co. Vasotec tablets (enalapril maleate) prescribing information. Whitehouse Station, NJ; 2002 Jan.

13. Ciba Pharmaceutical Company. Lotensin (benazepril hydrochloride) tablets prescribing information. In: Physicians’ desk reference. 49th ed. Montvale, NJ: Medical Economics Company Inc; 1995:887-90.

14. Bristol-Myers Squibb. Monopril (fosinopril sodium) tablets prescribing information. Princeton, NJ; 2002 Feb.

16. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1984; 26:107-12.

19. Moser M. Initial treatment of adult patients with essential hypertension. Part 1: why conventional stepped-care therapy of hypertension is still indicated. Pharmacotherapy. 1985; 5:189-95.

20. Kaplan NM. Initial treatment of adult patients with essential hypertension. Part 2: alternating monotherapy is the preferred treatment. Pharmacotherapy. 1985; 5:195-200.

21. World Health Organization/International Society of Hypertension Fourth Mild Hypertension Conference. 1986 guidelines for the treatment of mild hypertension: memorandum from the WHO/ISH. Hypertension. 1986; 8:957-61.

22. Subcommittee on Nonpharmacological Therapy of the 1984 Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Nonpharmacological approaches to the control of high blood pressure: final report. Hypertension. 1986; 8:444-67.

23. The Expert Panel (coordinated by the National Heart, Lung, and Blood Institute). Report of the Joint National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988; 148:36-69.

25. Alderman MH. Which antihypertensive drugs first—and why! JAMA. 1992; 267:2786-7. Editorial.

26. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153:149-52.

27. Weber MA, Laragh JH. Hypertension: steps forward and steps backward: the Joint National Committee fifth report. Arch Intern Med. 1993; 153:149-52.

28. Andrèn L, Weiner L, Svensson A et al. Enalapril with either a “very low” or “low” dose of hydrochlorothiazide is equally effective in essential hypertension: a double-blind trial in 100 hypertensive patients. J Hypertens. 1983; 1(Suppl 2):384-6.

29. Bauer JH, Jones LB. Comparative studies: enalapril versus hydrochlorothiazide as first-step therapy for the treatment of primary hypertension. Am J Kidney Dis. 1984; 4:55-64.

30. Vlasses PH, Rotmensch HH, Swanson BN et al. Comparative antihypertensive effects of enalapril maleate and hydrochlorothiazide, alone and in combination. J Clin Pharmacol. 1983; 23:227-33.

31. Fernandez PG, Kim BK, Galway AB. An appraisal of antihypertensive efficacy and adverse reactions with two drug regimens: enalapril maleate as part of triple therapy compared to conventional triple therapy in moderate to severe hypertension. Pharmatherapeutica. 1984; 3:505-14.

32. Guthrie GP Jr, Hammond J, Kotchen TA. Abrupt cessation of enalapril (MK-421) in essential hypertension. Clin Res. 1982; 30:733A.

33. Edling O, Gohlke P, Bao G et al. In vitro and in vivo characterization of the new ACE inhibitor moexipril: comparison with enalapril. Naunyn Schmiedebergs Arch Pharmacol. 1993; 347:R95.

34. DiCarlo L, Chatterjee K, Parmley WW et al. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations. J Am Coll Cardiol. 1983; 2:865-71.

35. Packer M, Lee WH, Yushak M et al. Comparison of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med. 1986; 315:847-53.

36. The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus). N Engl J Med. 1987; 316:1429-34.

37. Anon. Enalapril for hypertension. Med Lett Drugs Ther. 1986; 28:53-4.

38. Hodsman GP, Brown JJ, Cumming AMM et al. Enalapril in the treatment of hypertension with renal artery stenosis. BMJ. 1983; 287:1413-7.

39. Hodsman GP, Brown JJ, Cumming AMM et al. Enalapril in treatment of hypertension with renal artery stenosis: changes in blood pressure, renin, angiotensin I and II, renal function, and body composition. Am J Med. 1984; 77:52-60.

40. Bender W, La France N, Walker WG. Mechanism of deterioration in renal function in patients with renovascular hypertension treated with enalapril. Hypertension. 1984; 6(Suppl 1):I193-7.

41. Hricik DE, Browning PJ, Kopelman R et al. Captopril-induced renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med. 1983; 308:373-6.

42. Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs. 1986; 31:198-248.

43. Packler M, Lee WH, Medina M et al. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann Intern Med. 1987; 106:346-54.

44. Cody RJ. Clinical and hemodynamic experience with enalapril in congestive heart failure. Am J Cardiol. 1985; 55:36-40.

45. Packer M, Lee WH, Kessler PD. Preservation of glomerular filtration rate in human heart failure by activation of the renin-angiotensin system. Circulation. 1986; 74:766-74.

46. Packer M, Kessler PD, Gottlieb SS. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgrad Med J. 1986; 62(Suppl 1):179-82.

47. US Food and Drug Administration. Severe allergic reactions associated with dialysis and ACE inhibitors. FDA Med Bull. 1992; 22:4.

48. Parnes EL, Shapiro WB. Anaphylactoid reactions in hemodialysis patients treated with the AN69 dialyzer. Kidney Int. 1991; 40:1148-52.

49. Tielemans C, Madhoun P, Lenaers M et al. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int. 1990; 38:982-4.

50. Agishi T. Anion-blood contact reaction (ABC reaction) in patients treated by LDL apheresis with dextran sulfate–cellulose column while receiving ACE inhibitors. JAMA. 1994; 271:195-6.

51. Olbricht CJ, Schaumann D, Fischer D. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors. Lancet. 1992; 340:908-9.

52. Keller C, Grützmacher P, Bahr F et al. LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors. Lancet. 1993; 341:60-1.

53. Merck & Co. Vaseretic (enalapril maleate–hydrochlorothiazide) prescribing information. West Point, PA; 1994 Feb.

54. Merck & Co. Vasotec I.V. Enalaprilat (enalapril) prescribing information. West Point, PA; 1994 Apr.

55. Heel RC, Brogden RN, Speight TM et al. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs. 1980; 20:409-52.

56. Ferguson RK, Vlasses PH. Clinical pharmacology and therapeutic applications of the new oral angiotensin converting enzyme inhibitor, captopril. Am Heart J. 1981; 101:650-6.

57. Frohlich ED, Cooper RA, Lewis EJ. Review of the overall experience of captopril in hypertension. Arch Intern Med. 1984; 144:1441-4.

58. Vlasses PH, Larijani GE, Conner DP et al. Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. Clin Pharm. 1985; 4:27-40.

59. Bünning P. Inhibition of angiotensin converting enzyme by 2-[N-[(S)-1-carboxy-3-phenylpropyl]-l -alanyl]- (1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498 Diacid). Arzneimittelforschung. 1984; 34:1406-10.

60. Gavras H, Waeber B, Gavras I et al. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor MK-421. Lancet. 1981; 2:543-7.

61. Reviewers’ comments (personal observations) on enalapril; 1986 Nov.

62. Semple PF, Herd GW. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. N Engl J Med. 1986; 314:61.

63. Sesoko S, Kaneko Y. Cough associated with the use of captopril. Arch Intern Med. 1985; 145:1524.

64. Webb D, Benjamin N, Collier J et al. Enalapril-induced cough. Lancet. 1986; 2:1094.

65. Inman WHW. Enalapril-induced cough. Lancet. 1986; 2:1218.

66. Israel-Biet D, Delaisements C, Chretien J. Enalapril-induced cough. Lancet. 1986; 2:918.

67. Fennerty A, Littley M, Reid P. Enalapril-induced nasal blockage. Lancet. 1986; 2:1395-6.

68. Nicholls MG, Gilchrist N. Sulindac and cough induced by converting enzyme inhibitors. Lancet. 1987; 1:872.

69. Anon. Captopril: benefits and risks in severe hypertension. Lancet. 1980; 2:129-30.

70. Vlasses PH, Ferguson RK, Chatterjee K. Captopril: clinical pharmacology and benefit-to-risk ratio in hypertension and congestive heart failure Pharmacotherapy. 1982; 2:1-17.

71. Waeber B, Gavras I, Brunner HR et al. Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update. J Clin Pharmacol. 1981; 21:508-16.

72. Fruncillo RJ, Rocci ML Jr, Shepley K et al. Enalaprilat accumulates after chronic enalapril dosing in renal failure. Clin Pharmacol Ther. 1985; 37:197.

73. Schubiger G, Flury G, Nussberger J. Enalapril for pregnancy-induced hypertension: acute renal failure in a neonate. Ann Intern Med. 1988; 108:215-6.

74. Joint letter of Bristol-Myers Squibb Company; Ciba-Geigy Corporation, Pharmaceutical Division; Hoechst-Roussel Pharmaceuticals Inc; ICI Pharmaceutical Group, ICI Americas Inc; Merck Human Health Division; Parke-Davis, Division of Warner-Lambert Company. Important warning information regarding use of ACE inhibitors in pregnancy. 1992 Mar 16.

75. US Food and Drug Administration. Dangers of ACE inhibitors during second and third trimesters of pregnancy. FDA Med Bull. 1992; 22:2.

76. Piper JM, Ray WA, Rosa FW. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors. Obstet Gynecol. 1992; 80:429-32.

77. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325:293-302.

78. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685-91.

79. Anon. ACE-inhibitors: contraindicated in pregnancy. WHO Drug Information. 1990; 4:23.

80. Scott AA, Purohit DM. Neonatal renal failure: a complication of maternal antihypertensive therapy. Am J Obstet Gynecol. 1989; 160:1223-4.

81. Bennett WM, Aronoff GR, Golper TA et al. Drug prescribing in renal failure: dosing guidelines for adults. Philadelphia: American College of Physicians; 1987:36-7.

82. Varonier HS, Panzani R. The effect of inhalations of bradykinin on healthy and atopic (asthmatic) children. Int Arch Allergy Appl Immunol. 1968; 34:293-6.

83. Heritage Pharmaceuticals Inc. Uniretic Moexipril hydrochloride and hydrochlorothiazide tablets prescribing information. Eatontown, NJ; 2016 Nov.

84. Whelton PK, Appel LJ, Espeland MA et al. for the TONE Collaborative Research Group. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). JAMA. 1998; 279:839-46.

85. Food and Drug Administration. Univasc (moexipril hydrochloride) tablets [February 2, 2000: Schwarz]. MedWatch drug labeling changes. Rockville, MD; February 2000. From FDA website (

87. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4.

88. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20.

89. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61.

90. Associated Press (American Diabetes Association). Diabetics urged: drop blood pressure. Chicago, IL; 2000 Aug 29. Press Release from web site (

91. Schoolwerth AC, Sica DA, Ballermann BJ et al. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001; 104:1985-91.

92. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-60.

93. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97.

96. AstraZeneca. Zestril (lisinopril) tablets prescribing information. Wilmington, DE: 2002 Jan.

99. Novartis. Diovan (valsartan) tablets prescribing information. East Hanover, NJ; 2002 Aug.

103. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993; 329:1456-62.

104. Remuzzi G. Slowing the progression of diabetic nephropathy. N Engl J Med. 1993; 329:1496-7.

105. Kaplan NM. Choice of initial therapy for hypertension. JAMA. 1996; 275:1577-80.

106. Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA. 1994; 271:275-9.

107. Fournier A. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1994; 330:937.

108. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607.

109. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. Editorial.

110. Cooper WO, Hernandez-Diaz S, Arbogast PG et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006; 354:2443-51.

111. Food and Drug Administration. FDA public health advisory: angiotensin-converting enzyme inhibitor (ACE inhibitor) drugs and pregnancy. From FDA website (

112. Schwarz Pharma, Milwaukee, WI: Personal communication.

500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20.

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357.

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85.

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26.

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503.

506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4.

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6.

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8.

511. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008; 31:2115-27.

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88.

520. American Diabetes Association. Standards of medical care in diabetes--2014. Diabetes Care. 2014; 37 Suppl 1:S14-80.

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.

525. Smith SC, Benjamin EJ, Bonow RO et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011; 124:2458-73.

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :.

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425.

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8.

534. Qaseem A, Hopkins RH, Sweet DE et al. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013; 159:835-47.

535. Taler SJ, Agarwal R, Bakris GL et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013; 62:201-13.

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl.. 2012; 2:337-414.

541. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012; 33:1635-701.

543. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. K/DOQI Clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease (2002). From National Kidney Foundation website.

701. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37:2129-200.

702. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371:993-1004.

703. Ansara AJ, Kolanczyk DM, Koehler JM. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. J Clin Pharm Ther. 2016; 41:119-27.

800. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; 134:e282-93.